

Patient Information	Specimen Information	Client Information
DOB: AGE: Gender: Phone: Patient ID:	Specimen: Requisition: Lab Ref #: Collected: Received: Reported:	

COMMENTS: FASTING: YES

Test Name	In Range	Out Of Range	Reference Range	Lab
THYROID PANEL WITH TSH				
THYROID PANEL				
T3 UPTAKE	30		22-35 %	
T4 (THYROXINE), TOTAL	8.4		5.1-11.9 mcg/dL	
FREE T4 INDEX (T7)	2.5		1.4-3.8	
TSH	2.45		mIU/L	

Reference Range
 > or = 20 Years 0.40-4.50
 Pregnancy Ranges
 First trimester 0.26-2.66
 Second trimester 0.55-2.73
 Third trimester 0.43-2.91
 <5.7 % of total Hgb

HEMOGLOBIN A1c 5.2
 For the purpose of screening for the presence of diabetes:
 <5.7% Consistent with the absence of diabetes
 5.7-6.4% Consistent with increased risk for diabetes (prediabetes)
 > or =6.5% Consistent with diabetes

This assay result is consistent with a decreased risk of diabetes.

Currently, no consensus exists regarding use of hemoglobin A1c for diagnosis of diabetes in children.

According to American Diabetes Association (ADA) guidelines, hemoglobin A1c <7.0% represents optimal control in non-pregnant diabetic patients. Different metrics may apply to specific patient populations. Standards of Medical Care in Diabetes(ADA).

T4, FREE	1.0		0.8-1.8 ng/dL
T3, FREE	2.8		2.3-4.2 pg/mL
IGF 1, LC/MS	148		53-331 ng/mL
Z SCORE (FEMALE)	0.0		-2.0 - +2.0 SD

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

CORTISOL, TOTAL 6.1 mcg/dL
 Reference Range: For 8 a.m.(7-9 a.m.) Specimen: 4.0-22.0
 Reference Range: For 4 p.m.(3-5 p.m.) Specimen: 3.0-17.0
 * Please interpret above results accordingly *

Patient Information		Specimen Information		Client Information	
DOB:	AGE:	Specimen:			
Gender:		Collected:			
Patient ID:		Received:			
		Reported:			

Test Name	In Range	Out Of Range	Reference Range	Lab
DHEA SULFATE	176		23-266 mcg/dL	
FSH	7.1		mIU/mL	
	Reference Range			
	Follicular Phase	2.5-10.2		
	Mid-cycle Peak	3.1-17.7		
	Luteal Phase	1.5- 9.1		
	Postmenopausal	23.0-116.3		
INSULIN	4.1		2.0-19.6 uIU/mL	
	This insulin assay shows strong cross-reactivity for some insulin analogs (lispro, aspart, and glargine) and much lower cross-reactivity with others (detemir, glulisine).			
LH	2.9		mIU/mL	
	Reference Range			
	Follicular Phase	1.9-12.5		
	Mid-Cycle Peak	8.7-76.3		
	Luteal Phase	0.5-16.9		
	Postmenopausal	10.0-54.7		
PROGESTERONE	2.0		ng/mL	
	Reference Ranges			
	Female			
	Follicular Phase	< 1.0		
	Luteal Phase	2.6-21.5		
	Post menopausal	< 0.5		
	Pregnancy			
	1st Trimester	4.1-34.0		
	2nd Trimester	24.0-76.0		
	3rd Trimester	52.0-302.0		
ESTRADIOL	88		pg/mL	
	Reference Range			
	Follicular Phase:	19-144		
	Mid-Cycle:	64-357		
	Luteal Phase:	56-214		
	Postmenopausal:	< or = 31		

Reference range established on post-pubertal patient population. No pre-pubertal reference range established using this assay. For any patients for whom low Estradiol levels are anticipated (e.g. males, pre-pubertal children and hypogonadal/post-menopausal females), the Quest Diagnostics Nichols Institute Estradiol, Ultrasensitive, LCMSMS assay is recommended (order code 30289).

Please note: patients being treated with the drug fulvestrant (Faslodex(R)) have demonstrated significant interference in immunoassay methods for estradiol measurement. The cross reactivity could lead to falsely elevated estradiol test results leading to an inappropriate clinical assessment of estrogen status. Quest Diagnostics order code 30289-Estradiol, Ultrasensitive LC/MS/MS demonstrates negligible cross reactivity with fulvestrant.

SEX HORMONE BINDING

Patient Information	Specimen Information	Client Information
DOB: AGE: Gender: Patient ID:	Specimen: Collected: Received: Reported:	

Test Name	In Range	Out Of Range	Reference Range	Lab
GLOBULIN TESTOSTERONE, FREE (DIALYSIS) AND TOTAL, MS TESTOSTERONE, TOTAL, MS	22	150 H	17-124 nmol/L 2-45 ng/dL	

For additional information, please refer to <http://education.questdiagnostics.com/faq/TotalTestosteroneLCMSMSFAQ165> (This link is being provided for informational/educational purposes only.)

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

TESTOSTERONE, FREE	0.9		0.1-6.4 pg/mL	
--------------------	-----	--	---------------	--

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Patient Information	Specimen Information	Client Information
DOB: AGE: Gender: Patient ID:	Specimen: Collected: Received: Reported:	

Endocrinology

Test Name	Result	Reference Range	Lab
VITAMIN D,25-OH,TOTAL,IA	13 L	30-100 ng/mL	
Vitamin D Status 25-OH Vitamin D: Deficiency: <20 ng/mL Insufficiency: 20 - 29 ng/mL Optimal: > or = 30 ng/mL For 25-OH Vitamin D testing on patients on D2-supplementation and patients for whom quantitation of D2 and D3 fractions is required, the QuestAssureD(TM) 25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order code 92888 (patients >2yrs). For more information on this test, go to: http://education.questdiagnostics.com/faq/FAQ163 (This link is being provided for informational/educational purposes only.)			
Physician Comments:			

PERFORMING SITE: